BR112012004335A2 - composto, composição farmacêutica, e, uso do composto. - Google Patents
composto, composição farmacêutica, e, uso do composto.Info
- Publication number
- BR112012004335A2 BR112012004335A2 BR112012004335A BR112012004335A BR112012004335A2 BR 112012004335 A2 BR112012004335 A2 BR 112012004335A2 BR 112012004335 A BR112012004335 A BR 112012004335A BR 112012004335 A BR112012004335 A BR 112012004335A BR 112012004335 A2 BR112012004335 A2 BR 112012004335A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23924209P | 2009-09-02 | 2009-09-02 | |
| US26227809P | 2009-11-18 | 2009-11-18 | |
| PCT/US2010/046270 WO2011028455A1 (en) | 2009-09-02 | 2010-08-23 | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112012004335A2 true BR112012004335A2 (pt) | 2015-09-08 |
| BR112012004335A8 BR112012004335A8 (pt) | 2016-06-21 |
Family
ID=43649576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012004335A BR112012004335A8 (pt) | 2009-09-02 | 2010-08-23 | Composto, composição farmacêutica, e, uso do composto. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8455533B2 (pt) |
| EP (1) | EP2473047B1 (pt) |
| JP (1) | JP5734981B2 (pt) |
| KR (1) | KR20120092096A (pt) |
| CN (1) | CN102595897A (pt) |
| AU (1) | AU2010289871B2 (pt) |
| BR (1) | BR112012004335A8 (pt) |
| CA (1) | CA2771352A1 (pt) |
| IN (1) | IN2012DN00721A (pt) |
| MX (1) | MX2012002633A (pt) |
| RU (1) | RU2550508C2 (pt) |
| WO (1) | WO2011028455A1 (pt) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011103256A1 (en) | 2010-02-22 | 2011-08-25 | Merck Sharp & Dohme Corp. | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
| WO2011146358A1 (en) | 2010-05-21 | 2011-11-24 | Merck Sharp & Dohme Corp. | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
| WO2012078448A1 (en) | 2010-12-06 | 2012-06-14 | Schering Corporation | Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors |
| KR101668514B1 (ko) | 2011-02-25 | 2016-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체 |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| CA2836487A1 (en) | 2011-06-09 | 2012-12-13 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of gpr-119 |
| RU2598072C2 (ru) | 2011-06-29 | 2016-09-20 | Мерк Шарп И Доум Корп. | Новые кристаллические формы ингибиторов дипептидилпептидазы-iv |
| EP2729468A4 (en) | 2011-07-05 | 2015-03-18 | Merck Sharp & Dohme | TRICYCLIC HETEROCYCLES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS |
| EP2814485A4 (en) | 2012-02-17 | 2015-08-26 | Merck Sharp & Dohme | DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES |
| WO2014018350A1 (en) | 2012-07-23 | 2014-01-30 | Merck Sharp & Dohme Corp. | Treating diabetes with dipeptidyl peptidase-iv inhibitors |
| WO2014018355A1 (en) * | 2012-07-23 | 2014-01-30 | Merck Sharp & Dohme Corp. | Treating diabetes with dipeptidyl peptidase-iv inhibitors |
| TWI500613B (zh) | 2012-10-17 | 2015-09-21 | Cadila Healthcare Ltd | 新穎之雜環化合物 |
| CN105085528A (zh) * | 2014-05-15 | 2015-11-25 | 成都贝斯凯瑞生物科技有限公司 | 作为二肽基肽酶-iv抑制剂的氨基四氢吡喃衍生物 |
| EP3159344B1 (en) | 2014-06-17 | 2023-09-20 | Sichuan Haisco Pharmaceutical Co., Ltd. | Amino pyranoid ring derivative and composition and use thereof |
| JP6574474B2 (ja) | 2014-07-21 | 2019-09-11 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | キラルジペプチジルペプチダーゼ−ｉｖ阻害剤の製造方法 |
| CN105985357A (zh) * | 2015-02-12 | 2016-10-05 | 北京赛林泰医药技术有限公司 | 取代的氨基六元饱和杂脂环类长效dpp-iv抑制剂 |
| TWI681962B (zh) * | 2015-08-26 | 2020-01-11 | 大陸商四川海思科製藥有限公司 | 胺基六員環類衍生物及其在醫藥上的應用 |
| JP7141130B2 (ja) | 2017-05-31 | 2022-09-22 | ケモセントリックス，インコーポレイティド | Ｃ５ａ阻害剤としての６－５融合環 |
| CN107459501B (zh) * | 2017-08-22 | 2020-06-09 | 钟桂发 | 一种奥格列汀的手性中间体的制备方法 |
| WO2019154218A1 (zh) * | 2018-02-06 | 2019-08-15 | 四川海思科制药有限公司 | 一种氨基吡喃衍生物的组合物 |
| JP7337833B2 (ja) | 2018-04-02 | 2023-09-04 | ケモセントリックス，インコーポレイティド | 縮合二環式Ｃ５ａＲアンタゴニストのプロドラッグ |
| KR102131359B1 (ko) * | 2018-09-07 | 2020-07-07 | 오토텔릭바이오 주식회사 | 안정성이 향상된 의약 조성물 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US5232929A (en) | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
| US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US6054587A (en) | 1997-03-07 | 2000-04-25 | Metabasis Therapeutics, Inc. | Indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| AU6452098A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| EP0970095B1 (en) | 1997-03-07 | 2003-10-29 | Metabasis Therapeutics, Inc. | Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase |
| WO1999001423A1 (en) | 1997-07-01 | 1999-01-14 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| NZ507730A (en) | 1998-05-04 | 2004-02-27 | Point Therapeutics Inc | Hematopoietic stimulation |
| DE69910045T2 (de) | 1998-09-09 | 2004-04-22 | Metabasis Therapeutics Inc., San Diego | Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| GB9906715D0 (en) | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for promoting growth |
| HUP0201033A3 (en) | 1999-05-17 | 2003-03-28 | Novo Nordisk As | Glucagon antagonists/inverse agonists, process for their preparation and their use |
| AU2001277056B2 (en) | 2000-07-25 | 2005-09-29 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
| ZA200302394B (en) | 2000-10-27 | 2004-03-29 | Probiodrug Ag | Method for the treatment of neurological and neuropsychological disorders. |
| AU2002240235B2 (en) | 2001-01-30 | 2006-07-06 | Merck & Co., Inc. | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
| US7183290B2 (en) | 2001-06-27 | 2007-02-27 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
| DK1537078T3 (da) | 2002-08-29 | 2010-08-02 | Merck Sharp & Dohme | Indoler med anti-diabetisk aktivitet |
| JP4340232B2 (ja) | 2002-08-29 | 2009-10-07 | メルク エンド カムパニー インコーポレーテッド | 抗糖尿病活性を有するインドール類 |
| US7192922B2 (en) | 2002-11-19 | 2007-03-20 | Allegheny-Singer Research Institute | Method of treating left ventricular dysfunction |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| EP1587535A4 (en) | 2003-01-17 | 2010-02-24 | Merck & Co Inc | N-CYCLOHEXYLAMINOCARBONYL BENZENESULFONAMIDE DERIVATIVES |
| WO2005030751A2 (en) | 2003-09-08 | 2005-04-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| JP4963671B2 (ja) | 2004-06-21 | 2012-06-27 | メルク・シャープ・エンド・ドーム・コーポレイション | 糖尿病の治療または予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としてのアミノシクロヘキサン |
| WO2006020372A2 (en) | 2004-07-23 | 2006-02-23 | Neose Technologies, Inc. | Enzymatic modification of glycopeptides |
| US7718667B2 (en) | 2004-09-28 | 2010-05-18 | Merck Sharp & Dohme Corp. | Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| WO2006039325A2 (en) | 2004-10-01 | 2006-04-13 | Merck & Co., Inc. | Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| JP2008517921A (ja) | 2004-10-25 | 2008-05-29 | ノバルティス アクチエンゲゼルシャフト | Ｄｐｐ−ｉｖ阻害剤、ｐｐａｒ抗糖尿病薬およびメトホルミンの組合わせ剤 |
| AU2005309606B2 (en) | 2004-11-29 | 2011-01-06 | Merck Sharp & Dohme Corp. | Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| RU2396257C2 (ru) | 2004-12-20 | 2010-08-10 | Ф.Хоффманн-Ля Рош Аг | Производные 4-аминопиперидина |
| US7411093B2 (en) | 2004-12-20 | 2008-08-12 | Hoffman-La Roche Inc. | Aminocycloalkanes as DPP-IV inhibitors |
| EP1702916A1 (en) | 2005-03-18 | 2006-09-20 | Santhera Pharmaceuticals (Schweiz) GmbH | DPP-IV inhibitors |
| CN101500573A (zh) | 2005-05-25 | 2009-08-05 | 默克公司 | 用于糖尿病治疗或者预防的作为二肽基肽酶-ⅳ抑制剂的氨基环己烷 |
| DK1891105T3 (da) | 2005-06-13 | 2012-07-16 | Imp Innovations Ltd | Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd |
| ATE549926T1 (de) | 2005-08-26 | 2012-04-15 | Merck Sharp & Dohme | Kondensierte aminopiperidine als dipeptidylpeptidase-iv-inhibitoren zur behandlung oder prävention von diabetes |
| EP1962601B1 (en) | 2005-12-14 | 2014-10-15 | Merck Sharp & Dohme Corp. | Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes |
| US7750034B2 (en) | 2006-01-25 | 2010-07-06 | Merck Sharp & Dohme Corp. | Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| US7910596B2 (en) * | 2006-02-15 | 2011-03-22 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| CA2638800A1 (en) | 2006-02-22 | 2007-09-07 | Merck & Co., Inc. | Oxyntomodulin derivatives |
| JP2009530379A (ja) | 2006-03-20 | 2009-08-27 | メルク エンド カムパニー インコーポレーテッド | ニューロメジンｕ受容体アゴニスト及びその使用 |
| TW200806669A (en) | 2006-03-28 | 2008-02-01 | Merck & Co Inc | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| CN101410400B (zh) * | 2006-03-28 | 2012-09-05 | 默沙东公司 | 作为用于糖尿病治疗或者预防的二肽基肽酶-ⅳ抑制剂的氨基四氢吡喃 |
| EP2019677B1 (en) * | 2006-05-16 | 2013-08-14 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| CA2658286A1 (en) | 2006-07-18 | 2008-01-24 | Centocor, Inc. | Human glp-1 mimetibodies, compositions, methods and uses |
| US7855206B2 (en) | 2006-11-14 | 2010-12-21 | Merck Sharp & Dohme Corp. | Tricyclic heteroaromatic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| GEP20135944B (en) | 2007-02-15 | 2013-10-25 | Indiana Unversity Research And Tech Corporation | Glucagon/glp-1 receptor co-agonists |
| CA2691010A1 (en) | 2007-06-28 | 2008-12-31 | Merck Frosst Canada Ltd. | Substituted fused pyrimidines as antagonists of gpr105 activity |
| CA2693214A1 (en) | 2007-07-19 | 2009-01-22 | Merck Sharp & Dohme Corp. | Beta carboline derivatives as antidiabetic compounds |
| WO2009014676A1 (en) * | 2007-07-23 | 2009-01-29 | Merck & Co., Inc. | Novel crystalline form of a dihydrochloride salt of a dipeptidyl peptidase-iv inhibitor |
| CA2696211C (en) | 2007-08-21 | 2015-05-26 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| WO2009042053A2 (en) | 2007-09-21 | 2009-04-02 | Merck & Co., Inc. | Neuromedin u receptor agonists and uses thereof |
| CN102272135A (zh) | 2008-10-08 | 2011-12-07 | 百时美施贵宝公司 | 唑并吡咯酮黑色素浓集激素受体-1拮抗剂 |
| JO2870B1 (en) * | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
| EP2480082A4 (en) | 2009-09-25 | 2014-01-15 | Merck Sharp & Dohme | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES |
-
2010
- 2010-08-23 KR KR1020127005395A patent/KR20120092096A/ko not_active Application Discontinuation
- 2010-08-23 IN IN721DEN2012 patent/IN2012DN00721A/en unknown
- 2010-08-23 CN CN2010800391645A patent/CN102595897A/zh active Pending
- 2010-08-23 CA CA2771352A patent/CA2771352A1/en not_active Abandoned
- 2010-08-23 MX MX2012002633A patent/MX2012002633A/es active IP Right Grant
- 2010-08-23 US US13/390,538 patent/US8455533B2/en active Active
- 2010-08-23 BR BR112012004335A patent/BR112012004335A8/pt not_active IP Right Cessation
- 2010-08-23 EP EP10814188.8A patent/EP2473047B1/en not_active Not-in-force
- 2010-08-23 AU AU2010289871A patent/AU2010289871B2/en not_active Ceased
- 2010-08-23 RU RU2012112471/04A patent/RU2550508C2/ru not_active IP Right Cessation
- 2010-08-23 WO PCT/US2010/046270 patent/WO2011028455A1/en active Application Filing
- 2010-08-23 JP JP2012527901A patent/JP5734981B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8455533B2 (en) | 2013-06-04 |
| WO2011028455A1 (en) | 2011-03-10 |
| EP2473047A4 (en) | 2013-02-13 |
| RU2550508C2 (ru) | 2015-05-10 |
| MX2012002633A (es) | 2012-04-20 |
| BR112012004335A8 (pt) | 2016-06-21 |
| EP2473047B1 (en) | 2014-08-13 |
| JP5734981B2 (ja) | 2015-06-17 |
| IN2012DN00721A (pt) | 2015-06-19 |
| AU2010289871A1 (en) | 2012-04-26 |
| EP2473047A1 (en) | 2012-07-11 |
| CN102595897A (zh) | 2012-07-18 |
| US20120149734A1 (en) | 2012-06-14 |
| JP2013503864A (ja) | 2013-02-04 |
| AU2010289871B2 (en) | 2014-07-10 |
| RU2012112471A (ru) | 2013-10-10 |
| CA2771352A1 (en) | 2011-03-10 |
| KR20120092096A (ko) | 2012-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
| BRPI1007018A2 (pt) | composto, composição farmacêutica, e , uso de um composto. | |
| BRPI1008906A2 (pt) | composto, composição farmacêutica, e, uso de um composto. | |
| BRPI1010768A2 (pt) | composto, e, composição farmacêutica. | |
| BR112012002349A2 (pt) | composto,e, uso do mesmo | |
| BRPI0815709A2 (pt) | composro, composição farmacêutica, e, uso de um composto. | |
| BR112012031226A2 (pt) | composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica | |
| BRPI0906962A2 (pt) | Composto, e, composição farmacêutica | |
| BRPI0906556A2 (pt) | Composto, e, composição farmacêutica | |
| BR112013016772A2 (pt) | composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado | |
| BRPI1008793A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
| BRPI1016219A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0910503A2 (pt) | compostos, composições farmacêuticas e respectivos usos. | |
| BRPI0921375A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0814593A2 (pt) | Composto, composição farmacêutica que o contém e uso do composto. | |
| BR112013011448A2 (pt) | composto, composição farnmacêutica, e, uso do composto | |
| IT1403847B1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
| BRPI0917681A2 (pt) | Composto, e, composição farmacêutica | |
| BR112012003800A2 (pt) | composição, peptídeo, e formulação farmacêutica. | |
| BRPI1009757A2 (pt) | composto, composição farmacêutica, e , uso de um composto. | |
| BRPI0807078A2 (pt) | Composto, e, formulação farmacêutica | |
| BRPI0906937A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0915473A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI1007186A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0911772A2 (pt) | composto, composição farmacêutica, e, uso do composto. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: SCHERING CORPORATION (US) |
|
| B25D | Requested change of name of applicant approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
| B25G | Requested change of headquarter approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |